DNA based health tech company focused on obesity and cardiometabolic health

Live Fitgenes Australia Ltd

Fitgenes Australia

Fixed Priced Convertible NoteType of Offer
15 Oct 20Offer Open
17 Dec 20Pay By
Up to $600,000Size of Offer
$5,000 Minimum Investment
N/ALead Manager

This is a wholesale Convertible Note offer and is only open to Professional, Sophisticated and Experienced investors.  More information on how to qualify here.

Minimum application size of $5,000. OnMarket has a limited allocation under the Offer and the Company reserves the right to close the Offer early.



  • $5m cap on the note valuation
  • Strong growing revenue via major international distribution channels. 
  • Fitgenes is an Australian unlisted public DNA-based health-tech company focused on obesity; cardiometabolic health; and immunology, as well sports performance, physiotherapy, and sports injury recovery & nutrition.    
  • Delivers proprietary genomic profiling information and customised nutrigenomic data products - based on the genetic profile of the individual to help in the prevention and management of chronic diseases and injury.   
  • Nutrigenomics sector expected to double in size in the next 7 years to USD 919.8M by 2025.    
  • Personalised medicine market expected to grow to USD 1.7T by 2026.  
  • Fitgenes has a rapidly expanding channel of over 1,200 health practitioners  
  • Fitgenes is focused on major strategic partners  
    • Existing deal with leading Australasian healthcare company, Integria which services 9,500 health practitioners. 
    • Sales have commenced via a USA based Healthier2Gether with N.E. USA distribution, including 140 Medical Centres under contract, and prospective distribution to a $10B Healthcare Company New York, comprising 27 hospitals and 700+ medical centres.  Formal contract is in final stages of completion. 
  • Fitgenes is a revenue generating company with an established market position, health practitioner channel and a ‘best in class’ Therapeutic Goods of Australia listed technology platform.
  • $75,000 committed by the Directors to this raise
  • Rapid demand for its suite of products employed in clinical use by health practitioners in Australia, New Zealand, parts of Asia and increasingly Europe and USA.


Increasing burden of preventative chronic disease

  • Chronic disease destroying our quality of life.
  • Ageing population living longer with chronic disease.
  • The financial cost of preventing and treating ill health is substantial.  Australia spent about $170 billion on health in 2015–16—or almost $7,100 per person. 
  • 73 per cent ($117.0 billion) was able to be attributed to specific disease groups - such as diabetes, asthma, bronchitis, emphysema, arthritis and heart disease.

Obesity, diabetes and cardiovascular diseases a global health problem

  • Cardiovascular diseases (CVDs) are the number 1 cause of death globally
  • Obesity leads to cardiometabolic diseases including diabetes.


Global shift to nutrigenomic testing and intervention

  • New era of nutrigenetics/ nutrigenomics – the study of gene-nutrient interactions in the prevention of, and management of chronic diseases, such as coronary heart disease, hypertension, cancer, diabetes and obesity
  • Early detection of predisposition to chronic disease and intervention with diet and lifestyle changes. 
  • We now know that specific variations in our genes can explain how we will respond to the foods, beverages and supplements we consume.
  • Fitgenes is focused on obesity, immunity and cardiometabolic detection and prevention.

Nutrigenomics fast becoming mainstream

Genetics can provide crucial information on the causes and risk factors involved in obesity, diabetes, dietary issues and lifestyle.

Individualised, nutrigenomics is becoming a mainstream approach to chronic disease prevention.

Personalised medicine market and nutrigenomics testing market growth

Worldwide, genetics testing is increasing to create individual awareness of genetic illness predisposition.

Fitgenes is positioned in the global growth of nutrigenomics which is enabling early detection and prevention of chronic illness via dietary and supplement implementation.   This is enabling the overarching global growth of the personalised medicine market.

Market growth drivers

  • Increasing prevalence of obesity across the globe
  • Rising popularity for personalised diet
  • Increasing government initiatives on promoting health in developed regions such as North America and Europe
  • Rapid advances in molecular biology and genomics

Board of Directors



The offer

Fitgenes is seeking investment of up to AUD$600K by way of a convertible note. $75K investment commitment by the Directors.

Funds will be used to meet growing client demand and to further build out our technology to build momentum in preparation of a Series A raise commencing March 2021. 


Section 708 disclosure: The issuer of the securities is Fitgenes Australia Ltd ABN 99139 521 010. The securities to be issued are convertible notes. The information provided on the OnMarket website has been prepared by Fitgenes Australia Ltd, and OnMarket makes no representation as to its accuracy or completeness.  No prospectus has been prepared and accordingly, the Offer is being made to sophisticated, experienced and professional investors only.  

The Investor Presentation is intended to provide potential investors with information only and does not constitute a prospectus, short form prospectus or other disclosure document as defined in the Corporations Act 2001 (Cth) (“the Act”). This document has not been lodged with the Australian Securities and Investments Commission ("ASIC") or any other government body. The offer made under this Investor Presentation is only available for persons who qualify as sophisticated or experienced (as defined in s708(8)-(10) of the Act), professional investors (as defined in s708(11) of the Act), investors to whom personal offers are made under s708(1), or investors to whom disclosure is otherwise not required under Part 6D of the Act (collectively, “Qualified Investors”). 

Discover investment opportunities here

Equity Crowdfunding 13 days left

Road Runner Mobile Tyres Pty Ltd

Road Runner Mobile Tyres Pty Ltd
Disrupting the tyre retailing market as one of Australia’s largest and longest operating end-to-end mobile tyre services


Road Runner Mobile Tyres is one of Australia’s largest and longest operating end-to end mobile tyre services providing supply, fit, new tyres, wheel alignment and emergency tyre repairs. Operating in the major metropolitan markets of Sydney, Melbourne and Brisbane, they have successfully developed an operating system and customer focus that creates and maintains long term customer relationships.


Traditional tyre services require consumers to set aside much of their day driving to and waiting at the tyre service shop. Road Runner Mobile Tyres reduces the time and hassle of changing tyres for companies and car owners by providing a door to door service. Generating $2 million in revenue per annum and operating in a $5.6 billion market, Road Runner Mobile Tyres is changing the way people change their tyres.


Before investing please consider the offer document and the general risk warning.

Equity Crowdfunding Closing today

goPassport Australia Pty Ltd

goPassport Australia Pty Ltd
Digital health passport technology with potential to manage international travel with vaccine announcements by Pfizer and Moderna 


COVID-19 has caused a dramatic stop to international travel. QANTAS CEO Alan Joyce confirmed this week that proof that you've been vaccinated for COVID-19 will be compulsory for international air travel onboard his aircraft.


goPassport has created a digital health passport that provides an end-to-end COVID-19 compliance system for safe international travel. 


Before investing please consider the offer document and the general risk warning.

Min. reached - targeting $2 million







Equity Crowdfunding 11 days left

Cannatrek Ltd

Cannatrek Ltd
Medicinal cannabis leader in rapid growth mode, controlling the product lifecycle - "from seed to patient"


Register here for a LIVE VIRTUAL TOUR of cannabis growing facility on Tues 8 Dec at 1:00pm (AEDT)


Cannatrek Limited is a leading Australian medicinal cannabis company, developing production, manufacturing and digital healthcare distribution assets across Australia and globally.  The Company has a full suite of medicinal cannabis licences, providing complete control of the entire supply-chain and product lifecycle – "from seed to patient".


With an operational 3,200m2 growing facility in Queensland, yielding market ready product in commercial quantities, Cannatrek is also rolling out a digital healthcare platform for patients and healthcare professionals to serve the rapidly growing Australian medicinal cannabis market.


Before investing please consider the offer document and the general risk warning.

Min. reached - targeting $2.5 million




1 - 4%



IPO Live

Medallion Metals Ltd

Medallion Metals Ltd
Australian gold exploration and development company targeting 80,000 p.a. ounce production


Medallion Metals Ltd (ASX: MM8) is a resources exploration and development company looking to build a long life, high margin gold business in Australia with the initial focus on advancing the Ravensthorpe Gold Project located in the Goldfields-Esperance region of Western Australia.


With JORC compliant estimates of approximately 674,000 ounces of gold, the Company is focused on advancement of near mine exploration targets and updating the feasibility study completed in May 2020. The intention is to advance to final investment decision, and ultimately production targeting 80,000 ounces per annum. 


Medallion also owns the nearby Jerdacuttup Project, which is prospective for base and precious metals, and contains JORC Code compliant Mineral Resources estimates.

Up to $20 millionSize of Offer
19 Nov 20Offer Open
07 Dec 20Pay By
SPP Harvester Live

SPP Harvester

SPP Harvester
Harvesting the discount from Share Purchase Plans


The COVID-19 pandemic has caused a wave of discounted capital raisings with ~$56 billion of discounted new shares issued this year.


Share Purchase Plans (SPPs) allow individual shareholders to apply for up to $30,000 in shares at the same discounted price paid by institutions.  In the 6 months to 30 June, in-the-money SPPs were issued at an average 11% discount to the ASX closing price on the SPP closing date. But, you must be a shareholder before the SPP is announced.


SPP HarvesterTM gives you access to SPPs by buying you 1-share in 300 of the largest, liquid, operating companies listed on ASX.  It will identify and apply for in-the-money SPPs and automatically sell the new securities, efficiently recycling your capital into the next SPP. This automatically harvests the discount for SPPs, with minimum capital outlay, low establishment costs and minimal administration. 

UnlimitedSize of Offer
27 Nov 20Offer Open
11 Dec 20Pay By
Dual Listing Live

TruScreen Group Ltd ASX: TRU

TruScreen Group Ltd
Patented cervical cancer detection system, providing an accurate, real-time screening solution


The company has advised that they have reached the minimum subscription.


TruScreen Group Limited (ASX: TRU) manufactures and owns all rights to the patented TruScreen Cervical Cancer Screening System. The system uses an AI supported process to detect  pre-cancerous and cancerous tissue in real time and is at the forefront of the development of objective opto-electric tissue differentiation. The TruScreen solution aims to  improve the wellbeing of women and is ideal for communities that can’t access conventional laboratory dependant screening methods. 


The Company’s has distribution agreements in 23 countries with its products sold to China, Vietnam, Russia, Zimbabwe, Mexico, India, and Saudi Arabia. The Company is planning to establish a manufacturing plant in China as this currently accounts for over 50% of sales.  

~$1.85m (NZ$2m)Size of Offer
26 Nov 20Offer Open
17 Dec 20Pay By
Convertible Note Live

Fitgenes Australia Ltd

Fitgenes Australia Ltd
DNA based health tech company focused on obesity and cardiometabolic health


Fitgenes is an Australian unlisted public DNA based health tech company focused on obesity and cardiometabolic health. Fitgenes has developed a suite of comprehensive customised nutrigenomic data products which it sells and delivers to health practitioners in Australia, New Zea land, parts of Asia and increasingly Europe and USA.  Fitgenes has trained over 1200 practitioners on its Pracware platform, with plans to expand.


Established in 2002 with a goal to make optimal healthy living and healthy ageing DNA based information accessible to everyone.


This offer is restricted to professional, sophisticated and experienced investors.  More info here.

Up to $600,000Size of Offer
15 Oct 20Offer Open
17 Dec 20Pay By
Restricted Offer Live

COMtrac (IMA Pty Ltd)

COMtrac (IMA Pty Ltd)
Ground-breaking end-to-end investigation management system heralded by the industry as a game-changer to investigation management


COMtrac is a transformational investigation management technology solution business founded by Craig Doran, a former senior investigator with Queensland Police.  COMtrac is a proven solution to a problem widespread among multiple sectors – and provides a streamlined, superior level of rigor, transparency, consistency, and efficiency to the current investigative and evidence management process across law enforcement, insurance, legal firms, government, industrial relations, workplace complaints and incidents, consulting, banking and finance, and accounting institutions.


With a rapidly growing AAA customer base globally, COMtrac has already facilitated more than 180,000 investigations since launch with revenue already exceeding $1M this year with the investigation management solution set to transform the landscape and practice of investigation management.   


This offer is restricted to professional, sophisticated, and experienced investors.  More info here.

Up to $1.5 millionSize of Offer
25 Nov 20Offer Open
18 Dec 20Pay By
Equity Crowdfunding Upcoming

Foresense Technologies Ltd

Foresense Technologies Ltd
A disruptive innovator in real-time customer presence analytics

More Info

Foresense Technologies has developed an artificial intelligence solution enabling brick and mortar stores to more effectively compete with the growing presence of ecommerce. Proprietary technology allows retailers to understand and improve the experience and engagement of their customers.


Signed agreements with leading outdoor media company, a network of 4,000 newsagents across Australia, as well as final negotiations with a large US based casino group, a major national retailer and several other iconic global brands.


Foresense is positioning itself as a global leader in the customer presence and analytics market


Before investing please consider the offer document and the general risk warning.